Cargando…
The Effects of Encaleret (CLTX-305) on Mineral Physiology in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrate Proof-of-Concept: Early Results From an Ongoing Phase 2b, Open-Label, Dose-Ranging Study
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism caused by gain-of-function pathogenic variants in the gene (CASR) encoding the calcium-sensing receptor (CaSR). It is characterized by variable degrees of hypocalcemia, hyperphosphatemia, and hypomagnesemia, inappropr...
Autores principales: | Gafni, Rachel Ilana, Hartley, Iris Ruth, Roszko, Kelly Lauter, Nemeth, Edward F, Pozo, Karen A, Sani-Grosso, Ramei, Sridhar, Ananth, Kennedy, William D, Fox, Jonathan C, Collins, Michael T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090084/ http://dx.doi.org/10.1210/jendso/bvab048.545 |
Ejemplares similares
-
A Phase 2B, Open-Label, Dose-Ranging Study of Encaleret (CLTX-305) in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
por: Gafni, Rachel Ilana, et al.
Publicado: (2021) -
OR21-2 Encaleret (CLTX-305) Restored Mineral Homeostasis in a Phase 2 Study in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
por: Collins, Michael, et al.
Publicado: (2022) -
OR23-03 Sustained Normalization Of Mineral Homeostasis In Autosomal Dominant Hypocalcemia Type 1: Results From A Phase 2 Study Over 18 Months Of Encaleret (CLTX-305) Treatment (NCT04581629)
por: Ilana Gafni, Rachel, et al.
Publicado: (2023) -
SAT218 Refractory Hypocalcemia From Combined Autosomal Dominant Hypocalcemia Type 2 And Postsurgical Hypoparathyroidism
por: Sonmez Ince, Melda, et al.
Publicado: (2023) -
SAT225 An Unexpected Case Of Hypocalcemia
por: Nogueira Cordeiro, Monica Fabiola, et al.
Publicado: (2023)